Pneumococcal 15-Valent Conjugate Vaccine Provides Heightened Protection Against Certain Serotypes Compared With PCV13

Everyone aged 60 and over should be vaccinated against shingles, but only one in five does. Virologist Hartmut Hengel explains why the vaccine has amazing side effects.

Nearly 90% of the world’s population carries herpes, sometimes visible as cold sores, shingles or genital warts, sometimes dormant deep within the body. Studies show…

15-Valent Pneumococcal Vaccine V114 Found to Protect Against Serotypes 22F and 33F Not Covered by PCV13

A recent study has found that the 15-valent pneumococca […] The post 15-Valent Pneumococcal Vaccine V114 Found to Protect Against Serotypes 22F and 33F Not Covered by PCV13 first appeared on GeneOnline News. The post 15-Valent Pneumococcal Vaccine V114 Found to Protect Against Serotypes 22F and 33F Not Covered by PCV13 appeared first on GeneOnline News.

Pneumococcal 15-Valent Conjugate Vaccine Provides Heightened Protection Against Certain Serotypes Compared With PCV13

V114, a 15-valent pneumococcal conjugate vaccine (PCV), provided better protection against serotypes 22F and 33F compared with 13-valent PCV (PCV13).